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Abstract 
 
Endogenous levels of glucocorticoids rise during pregnancy to warrant development and maturation of the 
fetal organs close to birth. However, during most of the gestation, the fetus is protected from excessive 
biologically active endogenous glucocorticoids by placental and fetal expression of 11β-hydroxysteroid 
dehydrogenase 2 (11-HSD2). Maternal stress, which may overwhelm placental 11-HSD2 activity with high 
glucocorticoid levels, or administration of synthetic glucocorticoids to improve the survival chances of the 
premature newborn, are associated to postnatal increased risk for immune diseases. Fetal exposure to 
excessive glucocorticoids may underlie this altered postnatal immunity. Here, we revise the role that 
placental and fetal 11-HSD2, fetal glucocorticoid exposure and programming of the offspring’s the 
hypothalamic-pituitary-adrenal (HPA) axis play on concerted steps in immune fetal development. We could 
identify gaps in knowledge about glucocorticoid induced programming of immune diseases. Finally, based on 
current evidence about glucocorticoid and HPA axis mediated immune regulation, we hypothesize on 
mechanisms that could drive the enhanced risk for atopies, infections and type I diabetes in offspring that 
were prenatally exposed to glucocorticoids. 
 
Introduction 
 
In mammals, maternal physiological adaptations to pregnancy ensure appropriate fetal growth and 
development [1]. These multisystem adaptations include the modulation of endocrine signals, such as those 
derived from the hypothalamic-pituitary-adrenal (HPA) axis [2]. The gradual increase in maternal release of 
adrenal glucocorticoids during the second half of gestation accelerates as birth approaches[3]. Concurrently, 
the developing embryo is protected from maternal glucocorticoids throughout most of gestation by 
mechanisms that include feto-placental expression of the glucocorticoid-inactivating enzyme 11-
hydroxysteroid dehydrogenase type 2 (11-HSD2). These mechanisms may be inadequate in some 
circumstances, for example when maternal glucocorticoid levels are chronically elevated by stress, or 
evaded by synthetic glucocorticoids. Under these circumstances, exposure of the fetus to inappropriately 
high glucocorticoid levels impairs fetal growth and elicits neuroendocrine changes that persist into 
adulthood (termed “programming”) [4,5]. Given the higher incidence of atopic diseases in individuals who 
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were exposed to maternal stress prenatally and the potent immunomodulatory properties of glucocorticoids, 
concerns have been raised about potential long-lasting effects of excessive prenatal glucocorticoid exposure 
on the developing fetal immune system[6-8]. Here, we (i) review current knowledge of the factors that 
determine fetal glucocorticoid exposure, and (ii) review the evidence relating to mechanisms by which 
excessive prenatal glucocorticoid exposure may affect the immune system.  
Glucocorticoids in pregnancy 
 
Physiology of glucocorticoids during pregnancy 
 
The secretion of glucocorticoids (Box 1) is tightly controlled by the HPA axis. The cyclic activation of the axis 
results in the hypothalamic secretion of corticotrophin releasing hormone (CRH)[2], which stimulates the 
release of adreno-corticotrophin hormone (ACTH) from the pituitary. In turn, ACTH activates the adrenal 
release of glucocorticoids: cortisol in humans and most other animals, corticosterone in rats and mice[3]. 
The activity of the maternal HPA axis changes dramatically in pregnancy and post-partum (reviewed in[9,10]). 
Particularly during the second half of pregnancy, circulating glucocorticoids stimulate placental CRH 
synthesis[11-14]. CRH further stimulates pituitary ACTH release, which results in adrenal glucocorticoid 
production [15] and in a physiological state of “hypercorticolism”, with glucocorticoids rising dramatically 
towards parturition[16,17]. In late pregnancy, the HPA axis also becomes hyporesponsive to stress, probably 
due to a reduced forward drive from hypothalamic CRH and vasopressin, rather than to a change in negative 
feedback regulation[18]. As described below, high maternal glucocorticoids levels likely contribute to fetal 
organ maturation before birth. To some extent, the rise in maternal plasma levels of corticosteroid-binding 
globulin (CBG; Box 1) induced by high estrogen levels in late pregnancy offsets the high maternal 
glucocorticoid levels, by reducing the fraction of free, biologically available glucocorticoids[16]. Despite the 
high maternal glucocorticoid levels in the late human and rodent pregnancies, for most of gestation fetal 
plasma glucocorticoid levels are 5 to 10 times lower than in the mother, though levels rise markedly close to 
parturition to mature fetal organs[19-21]. However, intracellular glucocorticoid action is not solely 
dependent upon circulating glucocorticoid levels, but can be modulated by the activity of the 11-HSD 
enzymes. The type 2 isozyme, 11-HSD2, catalyses the inactivation of cortisol and corticosterone, generating 
intrinsically inert cortisone and 11-dehydrocorticosterone, respectively. In contrast, the type 1 isozyme, 11-
HSD1, catalyses the opposite reaction, regenerating active glucocorticoids. As reviewed below, these 
enzymes play distinct temporal and tissue-specific roles in the feto-placental unit during pregnancy. 
 
Glucocorticoid excess during pregnancy 
 
Endogenous glucocorticoids: Maternal stress 
 
Despite the hypo-responsiveness of the maternal HPA axis to stress in late pregnancy, it is still activated by 
strong or chronic stressors[22,23], including inflammation and infection[24]. Moreover, expression of 
placental 11-HSD2 can be suppressed by stress[25,2] and saturation of maternal CBG may lead to increased 
levels of free glucococorticoids in plasma[26]. All of these potentially lead to excessive fetal glucocorticoid 
exposure[23]. Intrauterine infection and  placental  inflammation  are  associated  with  fetal  glucocorticoid 
excess, as evidenced by a reduction in thymic size, a biological marker of glucocorticoid action, in human 
fetuses exposed to these situations in utero[27,28]. This could be at least partly mediated by maternal 
glucocorticoids, as a consequence of activation of the maternal HPA axis[23]. As well as affecting 
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glucocorticoid levels, the pronounced maternal immune system responses normally elicited by infection and 
inflammation could, of course, directly affect development of the fetal immune system, a large topic, 
beyond the scope of this review. Here, we restrict our discussion to the effects of maternal stress perception 
as a source of excessive fetal glucocorticoid exposure.  
 
Synthetic glucocorticoids 
 
Synthetic glucocorticoids are prescribed during pregnancy for several clinical indications. If the subject of 
treatment is the expectant mother, for instance to treat asthma and autoimmune disease such as systemic 
lupus erythematosus, or to prevent recurrent miscarriage in the first trimester of pregnancy, prednisolone is 
most commonly used, with doses being up to 40mg/day. Prednisolone and its inactive 11-keto metabolite, 
prednisone, are substrates for the 11-HSD enzymes (reviewed in[29,30]). However, high doses of 
prednisolone are likely to overwhelm the capacity of placental 11-HSD2, and reach the fetus. Prednisolone 
administered in the first trimester of pregnancy (weeks 4 to 13) did not have a teratogenic effect, but caused 
a two-fold increase in pre-term birth rate and reduced birthweight in term babies[31].  
 
Probably more relevant to fetal development are glucocorticoids administered to expectant mothers at risk 
of preterm delivery between 24 and 34 weeks of gestation[32], though benefit is seen even up to 36 weeks 
[33], in order to improve neonatal survival if the baby is born preterm. A single course of antenatal 
corticosteroids reduces morbidity due to acute respiratory distress in neonates and does not appear to be 
associated with overt short-term adverse effects on mother or fetus[32]. Importantly, however, a recent trial, 
conducted in low-resource settings, has shown no benefit of antenatal corticosteroid treatment in the 
mortality rates of very small infants, and a significant increase in neonatal mortality of infants born at later 
gestational ages[34]. Moreover, synthetic glucocorticoids suppress maternal and fetal HPA axis activity for at 
least one week after administration[35], and exert long-lasting effects upon the HPA-axis in children [36]. 
Despite the existing guidelines for prenatal steroid administration, more than half of the treated women do 
not deliver within the window of effect of the drug (less than 7 days), and repeated courses of steroids have 
proved detrimental rather than beneficial[37]. Betamethasone and dexamethasone are the steroids of 
choice to reach fetal organs if premature birth is imminent. Both have higher affinities for the glucocorticoid 
receptor (GR) than cortisol and neither is inactivated by 11β-HSD2 [38], a property that allows them to 
bypass feto-placental 11β-HSD2 but also ensures a longer half-life in the maternal circulation. Both bind 
poorly to CBG. Thus, these compounds cross the placenta readily, bypass 11β-HSD2 and are 25-fold more 
potent than endogenous cortisol (reviewed in[39]), causing a sizable peak of supraphysiological 
glucocorticoid bioactivity in the fetus, that only recedes three days after the second injection of 
betamethasone[40].  
 
Dexamethasone (1.5mg/day) is also used in cases of congenital adrenal hyperplasia to prevent 
masculinization of the female fetus. In this case, therapy starts as soon as pregnancy is recognized, and is 
continued until the end. A comprehensive metaanalysis[41] of the few available data (four studies, n=325 
pregnancies) reports a reduction in fetus virilization and no deleterious effects on stillbirths, spontaneous 
abortions or foetal malformations. Inconsistent results were reported on parent-reported behavioural and 
developmental outcomes later in life[41], and no data exist on metabolic, cardiovascular or immunological 
outcomes.  
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Regulation of fetal glucocorticoid exposure: Metabolism of glucocorticoids 
by 11-HSDs during gestation and fetal glucocorticoid production.  
 
Expression of 11-HSD1 and 11-HSD2 in the uterus  
 
Both 11-HSD1 and 2 are expressed in the uterus in the non-pregnant state, though they differ in their 
temporal and spatial distribution[42]. In rodents, 11-HSD1 is expressed in epithelial cells in the uterine wall 
whereas 11-HSD2 is present in the endometrial stroma and in the myometrium[42,43]. Expression of both 
enzymes is dependent upon estrogen[42]. In contrast, in human endometrium, 11-HSD2 is present in the 
glandular epithelium with little expression of 11-HSD1 until menstruation[44]. 11-HSD1 is markedly up-
regulated following decidualisation of human endometrial stromal cells[45], suggesting a possible role in 
embryo implantation. It has been suggested that glucocorticoid inactivation in the uterine wall contributes 
to the maintenance of the fetal allograft[46]. However, mice lacking 11-HSD2 are fertile and have normal 
sized litters[5], so any such role is moot. In pregnant rats, the marked up-regulation of 11-HSD1 in the 
myometrium shortly before parturition is dependent upon the feto-placental unit[47], suggesting a possible 
feed-forward regulation as glucocorticoid levels rise close to birth. However, 11-HSD1-deficient mice do not 
show a marked parturition phenotype, suggesting any effect on parturition is subtle.  
 
11-HSD2 expression in the feto-placental unit 
 
From as early as 5 weeks of human pregnancy, 11-HSD2 is expressed in the syncytiotrophoblast layer of the 
labyrinth zone of the placenta[48]. This syncytiotrophoblasts form the interface between the maternal and 
fetal circulations where nutrients and other substances are exchanged. During a normal pregnancy, 11-
HSD2 inactivates most of the maternal glucocorticoid passing through the placenta to the fetus[49,50]. By 
the end of the first trimester, 11-HSD2 becomes expressed in the cytotrophoblast and extravillous 
trophoblasts[48], potentially impacting placentation. Indeed, placentas of Hsd11b2-/- mice show altered 
structure and function, with reduced placental vascularization and altered nutrient transport[4]. The 
ontogeny of placental 11-HSD2 expression differs between species. In humans, 11-HSD2 expression 
remains high until parturition[51,52], maintained by human chorionic gonadotrophin activation of cAMP 
signaling[53], though 11-HSD2 activity may reduce close to birth[46,54]. Placental 11-HSD2 expression 
declines towards the end of gestation in the rat, and still earlier in the mouse (reviewed in[29]), with 
negligible levels of Hsd11b2 mRNA from E13[55] and enzyme activity markedly decreased by E16[50]. This 
decline in 11-HSD2 activity is likely to be due to[56], and contribute to, the late gestation rise in fetal 
glucocorticoid levels essential for maturation of fetal tissues and organs, which may differ in timing between 
species.  
 
11-HSD2 is also widely expressed in the fetus during early to mid-gestation, where it protects the 
developing tissues from inappropriate glucocorticoid exposure[55,57,58]. This protective role of 11-HSD2 
has been investigated in detail in the brain. Specific deletion of neuronal 11-HSD2, expressed here only in 
very early life, affects offspring behavior once adult[59]. These studies are important as the first to 
demonstrate a protective role for 11-HSD2 specifically in the fetus, distinct from the protective role of 
placental 11-HSD2. In most tissues in the mouse (mineralocorticoid target tissues being the exception), 
11-HSD2 expression decreases markedly in late gestation[55]. The same is likely true in humans[46]. 
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Reductions in placental 11-HSD2 activity associate with reduced birth weight and are found in a variety of 
conditions including intra-uterine growth retardation, maternal asthma, maternal undernutrition (reviewed 
in[29]) and maternal vitamin D deficiency[60]. Glucocorticoids are raised in at least some of these conditions, 
if not all and down-regulate placental 11-HSD2[56], though possibly only in late gestation[61]. The effect of 
exogenous corticosteroids on the regulation of placental 11β-HSD2 is still controversial: dexamethasone 
administered right before delivery increases levels of mRNA encoding 11β-HSD2 in sheep [61] and mice[62], 
while high levels of exogenous cortisol in late pregnancy decrease 11β-HSD2 enzyme activity in sheep [56]. 
 
In vitro, placental 11-HSD2 activity can be down-regulated or inhibited by a variety of factors. As well as 
glucocorticoids, hypoxia, and pro-inflammatory cytokines (IL-1 or TNF) reduce placental 11-HSD2 
expression[48,63-65], potentially offering a unifying glucocorticoid-mediated mechanism for the fetal 
programming effects of these different stressors [50]. Importantly, placental 11-HSD2 activity is reduced in 
human pregnancies complicated by pre-eclampsia[48,66].  Whether this reflects cause or effect is important 
to establish, though it is noteworthy that Hsd11b2-/- mice model aspects of pre-eclampsia, including intra-
uterine growth retardation[5,4,67]  
 
 
11-HSD1 expression in the feto-placental unit 
 
Although mRNA encoding 11-HSD1 is present in the rodent placenta[68], the corresponding activity is 
not[69]. Similarly, 11-HSD1 is little expressed in the fetus during most of gestation[68]. It becomes 
expressed close to birth, notably in the liver and lung[68,70], where it contributes to the maturational 
effects of glucocorticoids that occur just prior to birth[71]. 11-HSD1 is also expressed at term in the chorion 
and the amnion, the fetal membranes that together comprise the amniotic sac[52,46,72]. Glucocorticoids 
induce 11-HSD1 expression in cultured chorionic trophoblasts as well as amnionic fibroblasts[73] 
suggesting a feed forward mechanism to amplify glucocorticoid levels in the fetal membranes and the 
amniotic fluid, as birth approaches[72]. Moreover, whilst the pro-inflammatory cytokines IL-1 or TNF 
alone have only a modest effect on 11-HSD1 expression in human amnion fibroblasts, they potentiate its 
induction by glucocorticoids[74]  
 
The fetal HPA axis 
 
The fetal hypothalamic-pituitary-adrenal (HPA) axis becomes active in mid to late gestation, potentially 
contributing to the increase in fetal plasma glucocorticoid levels close to birth. Glucocorticoid synthesis 
initiates in the fetal adrenal gland around the 28th week of pregnancy in humans, and at embryonic day (E) 
14.5 in mice (reviewed in[21]). In mice, plasma glucocorticoid levels increase rapidly from E15, though in 
humans, levels only increase substantially in the week before birth. Negative feedback regulation of the HPA 
axis is established around E16.5 in mice[75]. The time at which the human HPA axis becomes responsive to 
the normal regulation is unclear. However, evidence suggests that HPA axis suppression occurs with 
intrauterine exposure to synthetic glucocorticoids[35], suggesting negative feedback of the HPA axis 
operates in the human fetus from the time of, or shortly after, initiation of adrenal glucocorticoid synthesis. 
Maternal undernutrition increases HPA axis activation in mice[50], though whether it also causes premature 
initiation of adrenal corticosteroid synthesis is currently unknown. However, this is likely given the ability of 
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the fetal HPA axis to compensate for maternal glucocorticoid deficiency with maternal adrenalectomy[76,50].  
 
Glucocorticoid sensitivity in the placenta and the fetus 
 
The main determinants of glucocorticoid sensitivity are the receptors: the higher affinity type 1 
glucocorticoid receptor (or mineralocorticoid receptor, MR) and the type 2 glucocorticoid receptor (GR). 
Expression of MR is negligible in the rodent placenta[69,55]. However, MR immunoreactivity, as well as 
evidence for the encoding mRNA, has been reported in human placenta [77]. Whether this reflects a true 
species difference requires confirmation. GR, by contrast, is expressed in the labyrinth zone of the placenta, 
and at higher levels in the basal zone, the main site of placental hormone synthesis and varies little through 
gestation[69,43,68].  
 
Within the fetus, MR and GR show negligible expression in the first half of gestation, at least in the 
mouse[55,68,78]. In mice, GR first appears in the fetus around E10, with initial sites of expression being the 
developing heart and the 3rd branchial arch[78], the latter giving rise to the thymus, which strongly expresses 
GR from E12.5[68]. From E12.5, GR expression becomes much more widespread. Thus, it is likely that the 
capability to respond to glucocorticoids via GR precedes, by up to several days depending on the tissue, the 
initiation of adrenal glucocorticoid synthesis at E14.5. MR, by contrast, shows little expression before 
E13.5[55]. There is transient expression of MR in muscle and a few other tissues between E14.5 and E18.5, 
but by E18.5, the distribution of MR expression is similar to the adult pattern. Importantly, however, MR is 
expressed in the developing thymus at E18.5, persisting into neonatal life[55], though expression has gone 
here by adulthood [79]. This suggests a window of susceptibility during which the thymus may be extremely 
sensitive to the effects of glucocorticoid, mediated either via GR[80] or MR. 
 
However, whilst essential, the presence of GR and/or MR by itself is not always sufficient for the response to 
glucocorticoids. For example, levels of GR do not associate with sensitivity to glucocorticoid-induced 
apoptosis in thymocyte populations[81]. Glucocorticoid resistance, despite expression of GR, is a well-known 
phenomenon in chronic disease states such as asthma, as well as in acute lymphoblastic leukemia. In the 
latter, resistance is associated with a Warburg type metabolism[82] and can be overcome by inhibition of 
glycolysis[83]. Acquisition of the ability to respond to glucocorticoids may depend on expression of 
“competence” factors[84], such as transcription factors, which act co-operatively with GR to effect 
glucocorticoid-mediated gene regulation. It is interesting to speculate that these may allow, or be facilitated 
by, a switch in metabolism as a direct or an indirect effect of glucocorticoid action[85]. Thus, many factors 
potentially regulate glucocorticoid sensitivity – acting upstream, downstream or cooperatively with 
GR[86,87,85], though the relevance to developmental actions of glucocorticoids is, as yet, largely unexplored. 
Further, glucocorticoid action in the fetus is likely to prime subsequent responses; the response of the 
tyrosine aminotransferase gene is more rapid following a second exposure to glucocorticoid, than following 
the first. This memory effect is mediated by glucocorticoid-induced gene demethylation at one site, required 
for glucocorticoid-dependent transcription factor recruitment to a second site[88]. We return to this topic of 
glucocorticoid sensitivity in the context of developmental programming, below. 
 
Consequences of fetal exposure to glucocorticoids  
 
Although glucocorticoids are essential for the maturation of fetal tissues and organs prior to birth[19,20], 
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excessive or possibly premature exposure to glucocorticoids during sensitive windows of development 
reduces tissue accretion and body weight, and elicits permanent effects on organs and tissues. These effects, 
which manifest in the offspring once adult, include hypertension, hyperglycemia, altered HPA axis activity 
and anxiety or depressive-like behaviours, increasing the risk of an individual for cardio-metabolic and 
psychiatric disease[89,21]. This phenomenon has been termed developmental “programming”. Maternal 
stress, which may overwhelm placental 11-HSD2 with high maternal glucocorticoid levels, programmes 
adult behavior and HPA axis responses[90-92] and increases allergic airway responses [93]. Early life 
programming of adult disease susceptibility also occurs with maternal under-nutrition and maternal 
infection[94]. Glucocorticoids are central to the programming that occurs with maternal under-nutrition[50], 
though whether they play a central role in programming by maternal infection is currently unknown and 
important to establish. Programming by glucocorticoids and/or stress has been described in humans, non-
human primates, sheep, rats and mice, as well as other animals and has been previously reviewed[89,29,95-
97]. 
 
As mentioned above, placental 11-HSD2 plays an important role in controlling fetal glucocorticoid exposure. 
In humans, mutations in HSD11B2 are associated with reduced birth weight[98]. In mice, maternal stress or 
the absence of 11-HSD2 reduces placental vascularization, causes placental dysfunction and alters nutrient 
transfer to the fetus[99,4,67] causing intrauterine growth restriction. Similarly, chronic glucocorticoid over-
exposure increases vascular resistance in the feto-placental circulation[100]. Together, these data suggest 
that placental dysfunction contributes to the programming effects of glucocorticoids. Recent evidence has 
shown that pravastatin administration, which increases placental vascular endothelial growth factor (VEGF)-
expression, to Hsd11b2-/- mice restores placental vascularization and rescues their IUGR phenotype[67], 
suggesting a possible therapy to overcome at least some of the adverse effects of fetal glucocorticoid excess.  
 
Programming by glucocorticoids depends upon windows of sensitivity -critical periods in the growth, 
development and/or maturation of the particular tissue or organ that is affected. For example, although 
dexamethasone administration in the third week of pregnancy in rats programmes hyperglycemia in adult 
offspring, administration of dexamethasone in the first or second week of pregnancy has no effect on 
glucose or insulin homeostasis[101]. Similarly, the children of women exposed to extreme maternal stress in 
the third trimester of pregnancy have altered basal cortisol levels at 1 year of age, whereas those exposed in 
the first trimester have normal cortisol levels [102].  Glucocorticoid resistance may be widespread in the 
early to mid-gestation fetus, in addition to the protection afforded by fetal expression of 11-HSD2. This 
requires further investigation, for example, to examine whether glucocorticoid resistance arises from the 
hypoxic environment or the dominance of glycolytic metabolism that predominates during early 
development or whether developing tissues need to express “competency factors” to acquire glucocorticoid 
sensitivity.  
 
The developmental windows of sensitivity to glucocorticoid action may differ between tissues. In GR-/- 
fetuses, impaired lung maturation is apparent by E15.5[103], whereas the impairment in heart maturation is 
not apparent until E16.5-E17.5[78]. For other organs that mature later, sensitivity can occur well into the 
neonatal period[104]. Thus, the programming effects of glucocorticoids, stress, poor nutrition or infection 
are not solely restricted to the prenatal period, but also impact during the neonatal period. For example, 
neonatal exposure to low doses of endotoxin programmes hyperactivity of the HPA axis and has long-lasting 
effects on immune regulation, including increased sensitivity of lymphocytes to stress-induced suppression 
of proliferation and protection from adjuvant-induced arthritis[104]. These windows of sensitivity for 
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particular organs are also likely to differ between species. For example, bone marrow hematopoiesis is 
largely established during the second trimester in humans, but only takes place shortly before birth in 
mice[105]. This suggests that the effects of maternal stress or other factors that determine fetal 
glucocorticoid exposure may be highly dependent on the developmental stage of the tissue or organ 
affected.  
 
Glucocorticoid-mediated programming of the hypothalamic-pituitary-adrenal axis 
 
Key to the mechanisms that underpin the long-term effects of maternal stress or glucocorticoid over-
exposure, is likely to be their effects on the fetal and/or neonatal HPA axis, leading to life-long HPA axis 
hyper-responsiveness[89,106,94,97]. In the case of maternal post-traumatic stress disorder, hypo-activity is 
programmed[102], though the mechanism is currently unclear. HPA axis hyperactivity plausibly accounts for 
the associations with metabolic (insulin resistance), cardiovascular (hypertension, increased coronary heart 
disease) and affective disorders (anxiety, depression). Given the potent immuno-modulatory effects of 
glucocorticoids[107,108], permanent changes in HPA axis activity are also likely to underpin at least some 
aspects of glucocorticoid programming of the immune system, though others are direct and mediated by GR 
and/or MR in fetal and/or neonatal immune tissues. In rodent models of stress/glucocorticoid programming, 
the HPA axis hyperactivity is mostly driven by increased hypothalamic expression of CRH and AVP[109] as 
well as altered GR/MR balance in the hippocampus[110]. However, although altered HPA axis responses are 
involved in the exacerbated pro-inflammatory response to LPS programmed by neonatal over-feeding, they 
are not centrally mediated. Instead, the adrenal response to ACTH following LPS challenge does not resolve 
efficiently, prolonging corticosterone release[111].  
 
 
Consequences of fetal glucocorticoid exposure on postnatal immunity 
 
Accumulating evidence from both animal and clinical studies suggests a link between prenatal glucocorticoid 
excess and programming of immune traits in the offspring. Although animal studies have provided valuable 
information on potential mechanisms, the findings are highly heterogeneous, possibly reflecting the 
multiplicity of hypotheses tested, as well as the species, strains and models used, as recently and thoroughly 
reviewed[105]. Here, we focus on clinical studies, which, due to the better defined samples and parameters 
assessed, as well as to the large number of individuals in epidemiological cohorts, provide more clear 
outcomes. Findings from the most outstanding clinical studies since 1980 that have addressed the 
programming of immune traits in postnatal life by maternal stress perception or prenatal steroid treatment 
are summarised in Tables 1 and 2, according to the study design: focused on early postnatal immune 
outcomes (Table 1), or epidemiology (Table 2).  
 
Table 1 provides clues on the short-term effects of glucocorticoid exposure on immunity. With few 
exceptions[112-115], fetal cord blood was employed to measure parameters such as cytokine levels, cell 
counts or leukocyte function, which we classified into innate or adaptive immunity (refer to Table 1 for 
references). Hampered by the considerable heterogeneity in immune parameters between individuals[116], 
differences in the selected readouts and methodologies employed, and the small size of these studies, the 
collective data are conflicting and inconclusive. For example, studies that have measured interleukin (IL)-6 in 
cord blood report decreased [117] or unchanged[118,119] IL-6 levels in response to the same prenatal dose 
of betamethasone. In another study in which second trimester maternal stress perception occurred, IL-6 
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levels increased[120]. The discrepancies between these studies could reflect the fact that cohorts exposed 
to antenatal steroids often include preterm neonates, in whom the immune system is still immature, in 
contrast to prenatally stressed neonates, largely born at term. After prenatal steroid treatment, studies 
broadly agree concerning alterations in cord blood lymphocytes, though differ in the individual cell 
populations affected. Total lymphocyte and CD4+ T cell numbers were decreased in one study[121] whereas 
in another study, T and NK cell numbers were unchanged though T cell proliferation was reduced and NK cell 
activation was increased[119]. Another study, in infants treated with antenatal corticosteroid, reported an 
absence of radiographic thymic shadow 36 h after birth, suggesting a decrease in thymic cellularity, but this 
was not associated with abnormal cell counts in peripheral blood[115]. Decreased neutrophil 
function[122,117] and a bias to immaturity[123] were observed in neonates following antenatal 
corticosteroid treatment, potentially increasing risk of morbidity and mortality from bacterial infection, as 
reported for multiple courses of glucocorticoids[124]. This, plausibly, could be due to HPA axis suppression, 
as a result of the treatment. More consistent outcomes were observed following prenatal stress exposure. 
For example, pro-inflammatory cytokine profiles[125,120], showed increases in IL-8 and IL-4 in cord 
blood[120] or in ex-vivo stimulated cells[125,114], though effects on IFN- were less clear. Higher IgE levels 
have been reported in cord blood of prenatally stressed newborns[126,127]. However the relevance of these 
findings is somewhat questionable, as fetal cord blood IgE is often contaminated with Ig of maternal 
origin[128]. Taken with caution, the collective data suggest that antenatal steroid treatment is detrimental 
for neutrophil function and the T lymphocyte compartment, whereas prenatal stress biases the 
inflammatory cytokine profile at birth towards a Th2 response. This Th2 bias in the cytokine response could 
be long lasting, as it is also observed in adolescents[129] and adult women[130] who experienced prenatal 
stress. Future studies with a greater number of participants as well as a comprehensive characterization of 
immune outcomes at birth or in neonates are needed to provide conclusive information on the short term, 
as well as long term, effects of endogenous or exogenous glucocorticoid exposure.  
 
In contrast, epidemiological studies (table 2) involving large cohorts and clear clinical outcomes have 
provided important insights into the mid and long-term consequences of prenatal endogenous and 
exogenous glucocorticoid exposure. Table 2 summarizes studies involving at least 100 participants, which we 
classified according to the nature of the immune disease and the age at evaluation of the symptoms. From 
23 epidemiological studies, 14 addressed the incidence of atopic diseases, predominantly asthma but also 
atopic dermatitis (refer to Table 2 for references). These studies, which ranged from 279 to 3.2 million 
participants, provide strong evidence that children exposed to prenatal stress are at a higher risk of 
developing atopic disease. Similarly, increased risk for asthma was observed in children prenatally treated 
with synthetic glucocorticoids[131]. Atopies are multifactorial diseases, exhibiting intensified Th2 responses, 
which drive high levels of IgE, and involve innate lymphoid cells, eosinophils and mast cells in particular 
[132,125].  
 
While classic genetic association studies can explain only 1-2% of variation in IgE levels, epigenetic 
associations account for more than 13% of IgE variation [133].  This suggests that environmental signals and 
developmental differentiation programs are influenced by epigenetic mechanisms that regulate sensitivity to 
asthma. The risk for atopy is increased from 1 until 14 years of age (refer to Table 2 for references), whereas 
beyond 14 years, the risk may be attenuated, though only one study addressed this [134]. The age at which 
these immune traits become apparent may be a measure of the endurance of effect of the prenatal insult. 
When the most affected ages are assessed within a cohort, variability suggests effects are most likely to 
manifest in early infancy[134,131] or during adolescence[8]. Similarly, the association of prenatal stress with 
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asthma was stronger either in girls[8] or boys[135] depending on the cohort analysed. These discrepancies 
could be driven by differences in the nature or timing of maternal stress during pregnancy, and highlight the 
requirement to report these and other maternal and offspring (such as gender and age) categories in the 
analysis of cohorts. 
 
Other studies addressed diverse diseases/immune traits that we have classified under the umbrella of “risk 
for infection”. Antenatal steroid treatment is associated with fewer systemic infections[32] in the immediate 
neonatal period. However, when multiple courses of prenatal glucocorticoids were given, the risk for 
perinatal infectious morbidity and neonatal death increased[124]. Further, in low and mid-income countries 
antenatal corticosteroid therapy was associated with greater overall infant mortality and an increase in 
suspected maternal infection [34], suggesting that glucocorticoids could negatively impact neonatal health 
by affecting maternal immunity. Increased antibiotic use[7] and hospitalization because of infectious 
diseases[136,137] in children aged 1 to 14 have been also reported, indicating that both antenatal stress and 
steroid therapy confer a greater susceptibility to infections or a weakened ability to resolve them. This could 
be related to multilevel dysfunction in the innate and adaptive immune responses, which might be primed 
by altered microbiome colonization, as discussed below.      
 
Similarly, an increased risk for autoimmune type 1 diabetes is associated with prenatal exposure to 
stress[138] or glucocorticoid therapy[139] in large cohorts of over 0.5 and 1.5 million participants, 
respectively. To date, no studies have examined associations between prenatal glucocorticoid exposure and 
other autoimmune diseases, which is not surprising given their relatively low frequency (compared to atopy), 
and late age of onset (mostly in adulthood, thus implying many years of follow up study). In addition to 
genetic risk, autoimmunity relies autoreactive T cells escaping negative selection, a process sensitive to 
glucocorticoids[140], and defects in immune regulation. Moreover, since children undergoing prenatal 
glucocorticoid therapy also have a higher risk for type 2 diabetes[139], it is likely that mechanisms that 
determine resistance to insulin or maintenance of beta cells are also affected by glucocorticoid therapy[141]. 
 
Finally, prenatal stress is also associated with an increased risk for any cancer [142], including acute 
lymphoblastic leukemia and Hodgkin’s disease[143]. Interestingly, the authors argue that these 
hematopoietic cancers may have an infectious etiology, being triggered by microbial agents or Epstein-Barr-
Virus[143], suggesting a link between prenatally-programmed susceptibility to infections and cancer.  
 
Thus, prenatal stress or corticosteroid treatment are associated with higher risk of atopy, infection, type I 
diabetes and cancer in later (postnatal) life. Despite the high heterogeneity in the experimental design 
among clinical studies (the prenatal steroid therapy or the proxy used for stress, the time of pregnancy 
evaluated, the postnatal time considered for assessing readouts, and the number and selection of 
participants), the mid/long-term clinical immune outcomes were surprisingly homogeneous. This, despite (at 
least in the case of stress, where the maternal immune and sympathetic nervous system are involved) the 
possibility of a variety of contributing mechanisms. This highlights the importance of glucocorticoids as key 
mediators of stress effects. Remarkably, just one study showed an association between increased evening 
cortisol and pregnancy-specific stress and both measures independently predicted the risk for infant 
illness[7]. The remaining clinical studies reviewed in Tables 1 and 2 did not measure glucocorticoids or failed 
to find their association with maternal stress[114], probably due to difficulties obtaining reliable 
glucocorticoid measures due to differences in time of day or stage of pregnancy. Moreover, as described 
above, maternal stress may decrease 11β-HSD2 expression/activity[25], resulting in fetal glucocorticoid 
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overexposure independently of maternal glucocorticoid changes. To close these gaps in knowledge, 
considerable efforts have been placed in improving experimental design and sample collection, which will 
undoubtedly provide more conclusive results in the near future. It is also possible that at least to an extent, 
the programming effects of glucocorticoids are direct upon the feto-placental unit, rather than secondary to 
effects upon maternal physiology[5,50]. Indeed, as mentioned above, there is a steep gradient between the 
high levels of glucocorticoid in the maternal compartment and low in the fetal. However, current evidence 
indicates significant “synchronization” between maternal and fetal immunity. Examples of this are apparent 
in the numbers of T regulatory[144] or Th2 cells[145]. This synchrony may result from the continuous 
exchange of hormones, immune messengers, antigens, and even cells[146,1], that takes place at the feto-
maternal interface. Clearly, stress-induced changes in transplacental transfer of maternal IgG or other 
passive immunity could also affect offspring immunity. Taken together, programming of immune disease by 
antenatal stress/corticosteroid therapy is likely to involve indirect mechanisms - changes in the mother 
eliciting fetal immune programming-, as well as direct effects on the placenta, fetal HPA axis and fetal 
immune organs. This requires further examination. Moreover, the time windows by which endogenous or 
exogenous glucocorticoids exert their programming effects during pregnancy might differ. Antenatal 
corticosteroid therapy is applied between 24 and 34 weeks of gestation [32] whereas maternal stress could 
take place outside of that window. We here referred to the existence of distinct windows of sensitivity, 
depending on the developmental immune process that takes place at each time and the sensitivity to 
glucocorticoids among tissues and stages of development, given by dynamic changes in the expression of GR, 
11β-HSDs enzymes and competence factor. Whilst the role of exogenous and endogenous insults with 
regards to the windows of sensitivity has been addressed extensively in animal research, to date, most 
clinical studies assessed stress only once in pregnancy without discrimination between timepoints (Tables 1 
and 2). An exception to this are the reports from Cookson et al. and Hartwig et al. that identify a higher risk 
of asthma with stress between 18-32/34 weeks, compared to earlier in gestation[8,6]. Interestingly, this 
later time point partially overlaps the window in which antenatal corticosteroid treatment is administered, 
suggesting that in humans, this could be the greatest window of sensitivity to the programming effects of 
glucocorticoids.  
 
In order to elaborate on potential mechanisms driving the increase in susceptibility to immune diseases 
following excessive prenatal glucocorticoid exposure, in the next section we will review the different stages 
of fetal immune development. While T cell responses are well known to be affected by glucocorticoids, we 
will additionally examine known or potential susceptibility to glucocorticoids by other components of innate 
and adaptive immune system, as they affect the risk for atopies, infections, and autoimmunity.  
 
 
Mechanisms that may underly glucocorticoid induced programming of the 
immune system 
 
Effect of glucocorticoids on the ontogeny of the fetal immune system: Hematopoietic stem 
cells and early hematopoietic niches 
 
Placental blood circulation is established on E9 in mice[147] and from the first trimester in human gestation, 
facilitating the nutrient and gas exchange between the fetal and the maternal systems. Thereafter, greater 
fetal exposure, especially at highly vascularized hematopoietic sites, to factors transferred from maternal 
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blood could be expected[148]. It remains unclear whether glucocorticoids affect the prenatal establishment 
of the definitive hematopoietic stem cell (HSC) pool, which endures through the individual’s life[149]. In the 
present section we review the development of the immune system aiming to pinpoint windows of sensitivity 
to glucocorticoids and possible immune or stromal cell targets. Though scarce, we here focus on evidence 
arising from fetal tissues, as distinct glucocorticoid responses in prenatal and posnatal tissues are possible, 
driven for example, by differential HSC DNA methylation patterns[150] and/or coexpression of transcription 
factors[151,152]. 
 
The fetal hematopoietic system develops in a stepwise manner that involves the formation, proliferation, 
migration and differentiation of HSC (reviewed in[153,154,149]). By E7 in mice and early first trimester in 
humans, hematopoiesis starts from transient precursors in the yolk sac [155]. These develop into 
erythrocytes and the first immune cells. From this hematopoietic wave, only tissue resident macrophages 
will endure until adult life. All other blood components will be gradually replaced by the definitive 
hematopoiesis [156]. Consequently, this early stage of hematopoiesis poses a low vulnerability for any long-
lasting effects of glucocorticoids on the immune system, in agreement with the lack of association between 
stress in the first trimester of gestation and the risk for atopic diseases[6,8].  
 
Definitive HSC are not found in the aorta-gonad-mesonephros region and in the placental labyrinth[157] 
until E10.5-11 in mice[158] and at 4-6 weeks of gestation in humans[159]. From 7 weeks of gestation in 
humans[160] and E12 in mice[158], definitive HSC migrate to the liver. Supported by the niche created by 
the arterial portal vascular tree[161], liver HSCs proliferate rapidly until E16.5 in mice[162], when HSC 
homing to the bone marrow starts. Simultaneously, differentiation of HSCs into myeloid cell lineages 
(erythrocytes, granulocytes, monocytes, megakaryocytes) as well as the development of the first lymphoid 
progenitors and then NK cells and B cells [163,164]. Some liver lymphoid precursors and HSC migrate to 
colonize the thymus and spleen and give rise to differentiated cells from the lymphoid and 
myeloid/erythroid lineages, respectively[165]. Although fetal growth and lung and cardiovascular 
development are rather refractory to glucocorticoids prior to E14.5[103,21,4], evidence concerning the in 
vivo effects of glucocorticoid exposure on fetal stages of hepatic hematopoiesis remains scarce. Early 
hematopoietic steps appear independent of glucocorticoids, as GR-/- fetuses show no distinct alterations in 
hepatic hematopoiesis at least until E14.5, when adrenal steroidogenesis initiates (unpublished 
observations). However, it is possible that GR can be activated by maternally-derived glucocorticoid before 
(or after) that. In mice, hepatic hematopoiesis coincides with a reduction in liver GR expression from E12. GR 
expression then rises significantly again at E18.5 when hematopoiesis has already been established in the 
bone marrow[68]. The decrease in GR expression on E14.5-18.5 together with high placental and hepatic 
11β-HSD2 expression during early to mid gestation are likely to be mechanisms to protect hematopoiesis 
from inappropriate glucocorticoid exposure at might occur in the case of maternal stress or infection. 
However, low GR expression does not prevent dexamethasone (a poor substrate for 11β-HSD2) from 
promoting the differentiation of immature hematopoietic cells (Lin−Sca-1+c-Kit+)[163] and Lin-c-KitLo 
lymphocyte precursors isolated from E15 mouse liver[151] into myeloid cells while at the same time 
disrupting their ability to form B lymphocytes in vitro[151]. Similar results were observed in adult human 
bone marrow[151], suggesting that this is a highly conserved effect of glucocorticoids. Thus, throughout 
fetal development, glucocorticoids may direct otherwise undifferentiated stem cells towards a myeloid cell 
fate over a lymphoid cell fate. In vivo a glucocorticoid-mediated impairment in lymphocyte differentiation 
may alter the B cell compartment in the short-term. This might explain the impaired neonatal humoral 
responses to tetanus [113] and Hepatitis B[114] vaccination in babies that received antenatal corticosteroid. 
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However, antenatal corticosteroid therapy was also associated with increased responses to Haemophilus 
influenzae type b [112], underscoring the need for more investigation on the role of prenatal glucocorticoids 
on humoral immune responses. 
 
The in vivo effects of glucocorticoids on immune cells are highly dependent on the type, dose, timing and 
duration of the treatment[166]. In human fetal (7-12 weeks of gestation) nucleated liver cells, in vitro 
betamethasone stimulation significantly inhibited the hematopoietic colony-forming capacity in a dose 
dependent fashion. This was evidenced by a reduction in the number of burst-forming units-erythroid cells 
(BFU-E) and colony-forming units for granulocytes, erythroid cells, macrophages and megakaryocytes (CFU-
GM and CFU-GEMM)[167]. Together these give rise to the myeloid blood components and/or erythrocytes. 
In contrast, it is well established that modest levels of dexamethasone promote self-renewal of early 
erythroid progenitors (BFU-E) and increase the production of terminally differentiated erythroid cells by fetal 
mouse liver cells in vitro and in vivo[168,169]. This seems relevant for immune function, since increased 
erythropoiesis may occur at the expense of a reduction in leukocyte hematopoiesis, as observed for in vitro 
lymphopoiesis[167]. A further unexplored question is whether glucocorticoid enrichment of BFU-E and the 
consequent increase in BFU-E derived CD71+ colony forming units erythroblast[168] might alter the 
suppressive CD71+ erythroid immune cell compartment. This neonatal cell population plays an important 
regulatory role in early neonatal immunity[170] by protecting the immature newborn against aberrant 
immune cell activation in the intestine upon colonisation with parturition-associated commensal 
microorganisms.  
 
Interestingly, while in human pregnancies the evidence for effects of prenatal stress on the immune system 
remains scarce[8,6], animal models pinpoint hepatic and bone marrow hematopoiesis as key susceptible 
sites, with corresponding developmental windows of sensitivity, for prenatal immune 
programming[171,172,105]. Effects specific to the different sites (or stages) are difficult to dissect, as very 
few studies limited the stress to just one of these stages[93]. Similarly, T cell development in the thymus 
takes place during an overlapping developmental window (see following section), at least in mice. Taken 
together, glucocorticoid over-exposure might simultaneously affect different processes of immune ontogeny. 
 
By E16.5 in mice and 13-14 weeks gestation in humans, bone vascularization and the concurrent transition 
from cartilage to a calcified matrix permit the HSC to migrate into the developing bone marrow 
(BM)[148,160] decreasing their number in the liver[153]. In the BM, the first quiescent adult-like HSC 
develop, probably as a result of their interaction with mesenchyme-derived stromal osteoblasts[148]. BM 
HSCs give rise to multipotent progenitors (MPPs) before differentiating into common myeloid progenitors 
(CMPs) and common lymphoid progenitors (CLPs), which then undergo a series of maturation steps. MMPs 
can replenish virtually all components of the immune system throughout life. Fetal BM HSC homing, self-
renewal and differentiation are highly dependent on the stromal niche[173]. Whilst glucocorticoids seem 
dispensable for fetal bone and cartilage formation[174], evidence suggests that glucocorticoid excess or 
deficiency affects the microstructure and function of the bone marrow. Bone resorption is enhanced in 
infants treated with at least four courses of antenatal steroids[175,176]. In vitro glucocorticoids promote 
proliferation of mouse perinatal osteoblasts [152] and promote maturation of human osteoblasts[166]. 
Importantly, newborn mice with chronically low glucocorticoid levels as a result of the transgenic deletion of 
the corticotropin releasing factor receptor 1 gene, show increased osteoblast-bound CXCL12[152], which 
enhances chemotaxis and quiescence in HSC. They also have more bone marrow and circulating 
hematopoietic stem and progenitor cells[152].  
14 
 
 
Concomitant with the sequential traffic of fetal HSCs through hematopoietic sites, immune cells circulate in 
growing numbers in the secondary lymphoid organs and vasculature[155], where they are susceptible to the 
effects of glucocorticoids. It seems plausible that glucocorticoid-induced programming of the immune 
system would be mediated by effects on HSCs or other persistent progenitors, rather than upon the 
continually replaced, short-lived fully differentiated cell populations. However, a direct glucocorticoid effect 
could explain short-term changes in infant immunity (for example, the increased susceptibility to infections). 
This could, in turn, affect immune responses in later life[143]. For example, methylprednisolone treatment 
of human umbilical cord blood CD34+ hematopoietic cell precursors accelerated NK cell differentiation and 
induced cytolytic activity[177]. It also promoted a switch in myeloid precursors toward immature NK 
cells[177]. Such a switch could explain the enhanced NK activation found in human cord blood cells of 
infants who received antenatal corticosteroid therapy[119]. 
 
Thus, further experimental investigation is required to establish whether and how excessive prenatal 
glucocorticoid exposure impacts upon HSC homing and proliferation and to determine any effects on 
hematopoiesis, with short and long term consequences for postnatal immunity. Key to the mechanisms, we 
hypothesize that long-lasting disease risk is driven by epigenetic mechanisms in HSCs, as outlined below.  
 
Effect of glucocorticoids in T cell differentiation and selection 
 
Shortly before birth, adrenal glucocorticoid production is low and circulating maternal glucocorticoids have 
been blocked by the placental 11β-HSD2 barrier. The thymic epithelium produces its own glucocorticoid to 
support the rapid development of the late gestation thymus[178]. Mouse thymic epithelial cells (mTEC) 
express the enzymatic machinery to convert cholesterol to corticosterone, suggesting that the level of 
glucocorticoids in thymus is enhanced by paracrine delivery. In mice, mTEC production of a glucocorticoid 
intermediate was highest at birth and subsided through adulthood[80,179]. Recently Taves et al. confirmed 
that corticosterone levels in the embryonic and neonatal thymic tissues are elevated above blood levels[180]. 
Production of corticosterone has been observed by thymocytes from older mice[181], and it  was proposed 
to underlie age-related thymic atrophy[178]. Immature thymocytes readily undergo apoptosis induced by 
glucocorticoids[182]. Since removal of glucocorticoids by adrenalectomy causes thymus hyperplasia, it was 
suspected that glucocorticoids play a role in thymocyte death by neglect. However, local production of 
glucocorticoids in the thymus and a normal thymus size in diverse GR-deficient models did not support this 
concept (reviewed in[183]). A recent report suggests that ACTH may act via its receptor, MCR2, to directly 
increase thymocyte numbers, independently of glucocorticoids [184], suggesting that perturbations of the 
HPA axis may regulate thymic homeostasis through ACTH as well as glucocorticoids. Glucocorticoids also 
counteract TCR-derived selection signals in thymocytes. By dampening the effect of TCR signals that would 
otherwise lead to negative selection, glucocorticoid signals allow TCRs with higher affinity for self-MHC to be 
positively selected. Consequently, transgenic mice with reduced GR signalling in immature thymocytes show 
a bias to a less autoreactive T-cell repertoire[185,186]. Enhancement of the T-cell repertoire by endogenous 
glucocorticoids has also been demonstrated by the reduced antigen responsiveness of mice with T cell-
specific disruption of GR signaling[187]. Of note, the first reported “knock out” of GR, that generated a 
truncated GR with residual activity[188,189], previously led to the conclusion that glucocorticoids play no 
role in thymic development[190,191]. However, while the thymocyte number and subset distribution of 
these mice were normal, their T-cell repertoires were not examined[190-192].  
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Elevated levels of glucocorticoid prenatally would be expected to add to the effects of endogenous thymic 
glucocorticoid production and further raise the threshold for negative selection, promoting the development 
of higher affinity and potentially auto-reactive T cells. Indeed, thymocyte apoptosis in the fetal thymus is 
induced by prenatal treatment with betamethasone at doses that mimic therapeutic levels [193]. This results 
in an accelerated refill of the thymic niche with immature precursors that are subject to selection in the 
presence of high glucocorticoid levels. Since 11β-HSD2 is not expressed in the fetal thymus, similar 
mechanisms could apply to excessive glucocorticoid exposure upon prenatal stress. Thus, expansion of a 
cohort of auto-aggressive T cells could underlie the increased incidence of asthma or autoimmune disease 
reported in the offspring of stressed or betamethasone-treated mothers[131,194]. 
 
Mechanistically, the antagonism of TCR and glucocorticoid signaling involves the glucocorticoid-inducible 
leucine zipper (GILZ) protein. Overexpression of GILZ in T-cell hybridomas inhibited TCR-induced 
apoptosis[195], implicating GILZ in glucocorticoid-mediated repression of TCR-induced transcription factors 
such as AP-1 and NF-kB. These factors are themselves direct targets of suppression by the GR, so GILZ may 
serve to amplify the repressive effects of glucocorticoids[196,197]. GILZ has been implicated in 
glucocorticoid effects in other immune cell types, in the dendritic cell-mediated expansion of Tregs[198,199], 
control of B cell survival[200] and endotoxin tolerance of macrophages[201]. Another potential target of 
glucocorticoid signaling during thymocyte selection is Nur77 (Nr4a1), whose transcriptional activity is 
sensitive to glucocorticoids[202] and its expression is upregulated by TCR signalling[203]. Transgenic 
expression of a dominant-negative form of Nur77 resulted in inefficient negative selection of autoreactive 
thymocytes [204]. In addition, thymocyte-specific deletion of all three Nr4a family members blocked 
development of regulatory T cells and caused fatal autoimmune disease similar to that of mice and humans 
lacking the Treg-specific transcription factor Foxp3[205].  
 
The elimination of autoreactive and potentially dangerous T cells before they leave the thymus constitutes 
the basis of central tolerance. While it is readily understandaable how central tolerance of T cells reactive 
against ubiquitous and thymic antigens is achieved, tolerance against tissue specific antigens such as insulin 
or myelin basic protein requires their “ectopic” or “promiscuous” gene expression by mTEC. This ectopic 
expression is dependent on the transcriptions factors such as AIRE[206] and FEZF2[207]. The regulated 
activity of these transcription factors ensures a representation of ‘self proteins’ in the thymic medulla which 
is displayed to maturing thymocytes during negative selection. Interestingly, a putative risk allele for Crohn’s 
disease is associated with the downregulation of AIRE expression mediated by glucocorticoids[208].  mTECs 
are also susceptible to glucocorticoids: Injection of high-dose dexamethasone in adult mice drastically, albeit 
transiently, depleted mTEC [209], which only resolved one week later. It is conceivable that a spike of 
glucocorticoid signaling at a sensitive time for the development of the T cell repertoire may compromise the 
transcription of tissue-restricted antigens in the thymus, thus impairing negative selection and favoring the 
production of autoreactive T cells. 
 
Molecular mechanisms that underpin glucocorticoid programming 
 
The mechanisms that underlie the permanent or programmed effects of glucocorticoids upon developing 
fetal tissues and organs remain unclear. Some aspects of stress/glucocorticoid programming can even be 
transmitted to future generations, without further experimental manipulation[210], raising interesting and 
important questions about the mechanism. A detailed overview of this topic is beyond the scope of this 
review, and so we restrict our discussion chiefly to mechanisms that may apply to immune programming. 
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Epigenetic variation has been suggested as a key mediator of the programming effects of glucocorticoids, 
with methylation of CpG residues in the promoter regions of key genes being implicated in the long-term 
effects of early life stress or glucocorticoid exposure[211,212]. However, no cause and effect relationship 
between methylation and long-term effects on physiology has yet been established [213]. Moreover, the 
relevance of the small differences in CpG methylation observed in most studies, particularly where these lie 
in largely methylation free CpG islands, to the transcriptional regulation of the associated programmed gene 
remains unclear. Clearer is the role of DNA methylation in HSC function and differentiation. 
 
 
Epigenetic mechanisms of fetal programming of immune cells 
 
As methylation can be transmitted from a cell to its progeny, variations in the HSC or HSPC methylation 
patterns, induced for example, by prenatal stress or glucocorticoid exposure, could have long-term effects 
upon the individual’s immunity. Epigenetic mechanisms have been implicated in regulation of fundamental 
stem cell functions, such as self-renewal and multilineage differentiation (reviewed in[214]). Plasticity in 
DNA methylation patterns is related to HSC multipotency, stage of ontogeny and aging[215,150] as well as to 
their degree of differentiation[216,217]. The few differences observed in the overall DNA methylation 
pattern between mouse fetal liver and young postnatal HSCs were suggestive of a developmental restriction 
process. In young HSCs, DNA methylation was gained on regions associated with non-hematopoietic lineages, 
and lost at genomic regions associated with blood cell production[150], seeming to favour an emerging 
transcription profile typical of leukocytes rather than fetal HSCs. De novo DNA methylation is required to 
maintain the self-renewal capacity of HSCs [218], whereas HSC differentiation is associated with changes in 
DNA methylation patterns. In this sense, myeloid lineage commitment involved less global DNA methylation 
than lymphoid commitment[216,217]. Interestingly, the methylation of genes involved in glucocorticoid 
receptor signalling pathways is altered when HSC commit to common myeloid and megakaryocyte-
erythrocyte progenitors[219], providing further clues that glucocorticoid related pathways are involved in 
HSC differentiation. In other tissues, glucocorticoid exposure has been suggested to lead to glucocorticoid 
resistance by inducing methylation of the GR gene promoter and suppressing its expression [220,221].  
However, the relevance of these differences in GR methylation for glucocorticoid sensitivity requires further 
examination. 
 
 
During development, T cell precursors become committed at the same time that alternative lineages are 
excluded. Several recent reports pinpoint dynamic changes in gene expression profiles and epigenetic 
marking over the process of T cell differentiation [222,223]. These demonstrate, for instance, how 
inheritable specification in helper and cytotoxic T cells involves stage-specific DNA methylation and 
demethylation events at the Cd4 locus[224]. Differentiation of Th2 cells is induced by activation of the T cell 
receptor and IL-4 receptors. Th2 phenotype is subsequently maintained by a positive feedback mechanism 
and by repressing histone modifications at Th1 loci[225]. With regard to the effect of stress/glucocorticoids 
on T cell epigenetic programming, a genome wide DNA methylation profile in T cells demonstrated that the 
methylation levels of 2872 CpGs differed significantly in adolescents whose mothers underwent stressful 
events during an ice storm in Canada, compared to controls[226]. Many of these differentially methylated 
CpGs occurred in genes and pathways related to immune function, suggesting that maternal stressors may 
affect postnatal immunity by long lasting and widespread effects on DNA methylation across the entire 
genome of their unborn children. A drawback of this study is that no sample was collected at birth, thus, 
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some of the changes could be related to postnatal stress events. In addition, no cause and effect 
relationships with DNA methylation have been established yet. This will be important to address in the 
future, as the epigenetic changes may occur secondarily to transcriptional programming. 
 
A clear example of prenatal programming of the immune system has been shown upon induction of innate 
immunity in pregnant mice. Injection of TLR agonists during pregnancy increases innate and adaptive 
immune responses in the offspring, and results in earlier onset of clinical symptoms of experimental 
autoimmune encephalitis[227]. Even though the underlying mechanisms were not evaluated, these 
experiments indicate that fetal programming of the immune system persists into adulthood and has 
consequences for health. 
 
Potential mechanisms of glucocorticoid induced postnatal immune disease 
 
The effects of glucocorticoids on the immune system are amazingly broad as a consequence of the variety of 
target cell types, the diversity of pathways affected, the time of action and a seemingly dichotomous effect 
on the immune response: glucocorticoids tend to enhance a ramp up innate response to microbial products 
and damaged tissue, while repressing subsequent adaptive immune responses, to promote the resolution of 
inflammation and restore homeostasis[228,229]. It is not surprising that, when looking at the consequences 
of fetal exposure to glucocorticoids as a result of maternal stress or by pharmacological indication, we find 
apparently discordant effects, namely exacerbated responses in atopy or insufficient immunity to infection.  
 
A converging point of published studies on prenatal stress is an increased risk of developing allergies. Atopy 
is characterized by dominant Th2 responses, with an overproduction of Th2 cytokines such as IL-4 and IL-13, 
and high IgE levels in serum, leading to enhanced mast cell degranulation. Th2 responses have long been 
considered the anti-inflammatory counterpart of Th1 and, by suppressing IL-12 and IFN-γ, glucocorticoids 
shift the Th1/Th2 balance to Th2[230]. This process may be mediated, at least in part, by GILZ[231]. 
Psychological stress enhanced Th2 responses in asthmatic patients, detectable even one year after the 
stressful event[232]. Moreover, production of Th2 cytokines was increased in 13 year old children and adult 
women born from mothers who faced stressful conditions during pregnancy[129,130]. Together, these 
studies indicate programming of enhanced Th2 responses by stress and/or glucocorticoids. Interestingly, 
epigenetic mechanisms had 10-fold greater influence on the levels of serum IgE in asthmatic patients than 
classical inheritance of genetic traits[133], underlining the importance of epigenetic transmission of Th2 
responses. 
 
Importantly, atopic diseases such as asthma may have a multifactorial etiology[233]. In humans, mid to 
severe subtypes of asthma show altered airway remodeling, resembling developmental branching 
morphogenesis of the lung. This results from disease-mediated epithelial metaplasia and damage and 
hypertrophy and hyperplasia of mesenchymal airway smooth muscle[234,235]. Similarly, in mice, conditional 
deletion of GR in lung mesenchyma results in an immature lung phenotype and deletion of GR in lung 
epithelium increases cellularity of epithelial and non-epithelial compartments [236]. Thus, it is tempting to 
hypothesize that precocious or excessive prenatal glucocorticoid exposure promotes structural changes in 
the immature lung which could synergize with glucocorticoid driven immune alterations to enhance the 
vulnerability to airway diseases. 
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In addition to direct effects upon the maturing lung and immune system, programmed HPA hyper-
responsiveness as a result of prenatal stress or exogenous glucocorticoid exposure may play a role in 
hypersensitivity to antigens in atopy[237]. For example, hypothalamic CRH responses, increased upon 
prenatal stress[109], promote mast cell degranulation[238]. Other mechanisms previously reviewed 
elsewhere [239,237], that involve substance P, arginine vasopressin or ACTH, may also contribute to atopy 
by potentiation of systemic immune proinflammatory effects. Of note, while the association between 
prenatal glucocorticoid induced immune and HPA dysfunction has been frequently demonstrated in animal 
studies (as detailed above), direct evidence remains scarce in humans. None of the studies summarized in 
tables 1 and 2 assessed HPA responses in infants. Similarly, as described above, increased prenatal exposure 
to glucocorticoids decreases birth weight and is associated with placental insufficiency. Low birth weight is 
also an important predictor of enhanced risk of developing asthma[240,241] and atopic dermatitis[242]. 
Whether the reductions in birth weight, alterations in lung structure and function and Th2 bias are all 
mechanistically related through excessive prenatal glucocorticoid exposure is an important question for the 
future.   
 
At physiological concentrations, glucocorticoids exert potent immuno-modulatory effects[107]. 
Glucocorticoids alter dendritic cell function, rendering them tolerogenic[198], plausibly mediated by GILZ, 
and they promote LPS tolerance in previously activated macrophages[201]. Thus, programmed postnatal 
HPA axis hyper-responsiveness and concurrent elevated basal cortisol levels could influence immune 
responses in the offspring. Moreover, there is growing evidence that development of the immune system in 
the offspring depends on the intestinal microbiota (reviewed in [243]). In this context, a recent study 
reported that infants of highly stressed mothers with high cortisol concentrations during pregnancy showed 
aberrant colonization with abundant Proteobacterial groups (containing pathogens related to Escherichia, 
Serratia, and Enterobacter), and reduced commensal bacteria, such as Lactobacillus[244]. In addition to the 
reported higher incidence of gastrointestinal symptoms and allergic reactions in these infants, the abnormal 
microbiota could elicit long lasting changes in the composition of the immune system, resulting in, for 
example, an enhanced infection risk. Moreover, prenatal stress exposure as well as antenatal corticosteroid 
treatment or preterm birth can prime the risk for diseases in early postnatal life[7,245]. This, in turn, may 
exert long-lasting effects upon HPA responses[104]. Thus, the independent contributions of prenatal and 
postnatal factors may be difficult to tease apart. 
 
Autoimmune diseases may be affected by prenatal glucocorticoid exposure. Children exposed prenatally to 
stress or corticosteroid therapy are at increased risk of developing type 1 diabetes (Table 2). Type 1 diabetes 
results from the destruction of the beta cells in the pancreatic islets by infiltrating autoreactive 
lymphocytes[246]. Transcripts encoding insulin, the main autoantigen in diabetes, are expressed in the 
thymus, driven by Aire [247]. Thus, a glucocorticoid-induced depletion of mTEC[209], or a direct effect of 
glucocorticoids on the regulation of Aire[208], could impair negative selection of lymphocytes recognizing 
insulin[248]. In addition, as we have mentioned before, by antagonizing TCR signaling, glucocorticoids 
modulate the threshold between positive and negative selection of thymocytes[185,80]. Excessive 
glucocorticoid signaling (due to prenatal corticosteroid treatment or as a result of HPA hyper-
responsiveness) could improve the survival of T cells prone to autoreactivity that otherwise would have been 
eliminated in the thymus. Beyond effects on the immune system, GR signaling determines beta cell 
differentiation during a critical developmental window through the regulation of the pancreatic master 
transcriptional regulator, Pdx-1[141]. A better maintenance of beta cells could slow down development of 
the disease. 
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In summary, mechanisms for glucocorticoid mediated programming of immune diseases may include short 
and long term changes in the immune system that interact with HPA axis hyper-activity and potentially with 
prenatally programmed altered function of the affected organs. Figure 1 depicts a hypothetical scenario, 
where the known or potential interactions between these players are illustrated, as well as their relation to 
postnatal immunity. The complexity of this scenario explains the difficulties of dissecting out the roles and 
understanding the hierarchical action of the individual players. 
 
Final remarks 
 
Epidemiological data unambiguously reveal prenatal life as a relevant period for programming of immune 
diseases. We have restricted this review to intrauterine immune development and the maternal, placental 
and fetal factors that may be modulated by glucocorticoid over-exposure in the settings of prenatal stress or 
synthetic glucocorticoid administration. However, maternal stress effects on offsprings’ immunity exceed 
the pregnancy period, and maternal prenatal stress is associated to postnatal stress/anxiety, which can also 
programme i.e. the risk for asthma[249]. Not to be forgotten is the influence of postnatal care[250] and 
lifestyle of the child, which may exert further effects on the immune system.  
 
Despite all the evidence, very little is known about the mechanisms that lead to immune disorders, and how 
they are programmed during fetal life. Moreover, crucial milestones of fetal immune development are 
achieved comparatively earlier in humans compared to mice and, consequently, the windows of sensitivity 
to glucocorticoids during fetal life are also likely to be different. For these reasons, there is an acute need for 
analysis of large cohorts, in which women are recruited early during pregnancy with follow-up of their 
offspring beyond puberty. In addition to strict documentation of the time window at which stressful events 
or treatment occurred, such studies should include a broad assessment of the child’s immune compartment 
and function at birth and later in life. This strategy should provide the much sought-after biomarkers to 
assess disease risk, and identify targets for mechanistic research in glucocorticoid-mediated programming of 
the immune system.  
 
Given the steady increase in atopy and autoimmune disease over the last few decades[251], investigating 
the windows of sensitivity to maternal stress/antenatal glucocorticoids and the multiplicity of factors 
involved in the programming of the immune system will permit the design of prevention strategies and 
constitute a true investment in our health. 
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Table 1: Changes in the innate and adaptive immune systems observed at birth and in early postnatal life 
  Condition 
Sample 
analyzed 
n Innate immunity 
Adaptive immunity 
References 
Cells Function Ab resp.  
Betamethasone 
(RDS Tx) 
CB 
In vitro 
18 
 Neutr. migration  
 Neutr. chemotaxis    
Fuenfer, 
1987[122] 
Betamethasone 
(RDS Tx) 
CB 84 
 Neutr. counts 
 Immature neutr.     
Barak, 
1992[123] 
Betamethasone 
(RDS Tx) 
CB serum 125 
 IL-6  
 ROS     
Caldas, 
2012[117] 
Betamethasone 
(RDS Tx) 
CB serum 200 
 IL-1β, IL-6, TGF-β 
 IL-10, IL-8, IL-4    
Kumar, 
2011[118] 
Betamethasone 
(RDS Tx) 
CB cells 
In vitro 
51  IL-6  
 T cells 
 NK cells 
 T cell prolif.  
 NK activation  
Kavelaars, 
1999[119] 
Antenatal steroids  
(not specified) 
Cord blood 42 
 
 Lymphoc.  
 CD4+   
 CD25+ 
  
Chabra, 
1998[121] 
Betamethasone 
(RDS Tx) 
CB cells 100 
 
 Lymphoc.   Apoptosis  
 
Agakidis, 
2009[252] 
Dexamethasone 
(RDS Tx) 
Chest X-ray 
at <36h life 
50 
 
No thymic 
shadow   
Michie, 
1998[115] 
Betamethasone 
(RDS Tx) 
Serum after 
vaccination 
54 
   
 Hib  
Tsuda, 
2012[112] 
Betamethasone 
(RDS Tx) 
Serum after 
vaccination 
130 
   
  
Tetanus  
Slack, 
2004[113] 
Maternal anxiety  
(20 &32 WOG) 
CB serum  
Blood at 2m 
120
9   
 T cells 
 IFN- 
 IL-4 
 HBV  
O'Connor, 
2013[114] 
Maternal stress  
(end of pregnancy) 
CB cells 
In vitro 
 
557 
 IL-8,  IFN-  
after TLR stimulation  
 IL-13 after 
mite dust stim. 
 IFN- after 
PHA stim. 
 
Wright, 
2010[125] 
Maternal stress  
(2nd trimester) 
CB serum 43 
 IL-1β, IL-6,  
IL-12, TNF-α 
 IL-8 
 IL-4, IL-5 
   
Andersson, 
2016[120] 
Maternal negative life 
events (29 WOG) 
CB serum 403 
   
 IgE 
Peters, 
2012[126] 
Maternal selfreported 
psychosocial stress 
CB serum 334 
   
 IgE Lin, 2004[127] 
CB: Cord blood; ROS: Reactive oxygen species; n. sp. Not specified which; WOG: weeks of gestation; Neutr.: Neutrophil.;  
PHA: phytohaemagglutinin; IgE, immunoglobulin E; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; m: months;  
Ab resp., antibody response 
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Table 2: Epidemiological studies showing association between prenatal stress or steroids and immune diseases 
 
Disease Condition Study cohort Association to disease Reference 
Atopy 
Maternal high stress 
N= 1264 
Until 2 yr 
 risk atopic disease Wen, 2011[253] 
Prenatal stress: 
negative life events 
N= 653 
Until 2 yr 
 wheezing in children born to mothers nonsensitized 
(low IgE) 
Mathilda Chiu, 
2012[254] 
Prenatal community 
violence 
N= 708 
Until 2 yr 
 association with wheezing Chiu, 2014[255] 
Prenatal maternal 
distress (a), depression 
and anxiety (b) 
N= 1531 (a) + 
973 (b) 
Until 4yr 
 risk for atopic dermatitis (a,b) 
in prenatal stress + atopic dermatitis: 
 serum IgE levels at 1 year of age 
Chang, 2016[25] 
Prenatal demoralization 
(i.e. psychol. distress) 
N= 279 
Until 5 yr 
 transient and persistent wheeze 
 IgE CB/blood 
Reyes, 2011[256] 
Maternal psychological 
distress (20 WOG) 
N= 4848 
1-6 yrs 
 odds of wheezing in 1-4 yrs 
 asthma and eczema at age 6 years 
Guxens, 2014[257] 
Prenatal (and 
postnatal) stress 
N= 765 
6 yrs 
 asthma in boys prenatally or postnatally stressed 
 asthma in prenatally + postnatally stressed girls  
Lee, 2016[249] 
Maternal psychosocial 
job strain 
N=32.104 
Until 7 yr 
 atopic dermatitis in high strain job;  
 asthma in active jobs  
Larsen, 2014[258] 
Maternal anxiety  (18 
and 32 WOG) 
N= 5810 
Until 71/2 yr 
 likelihood for asthma if high anxiety at WOG 32 Cookson, 2009[6] 
Antenatal steroids 
N=80448 
Until 8 yr 
 risk of asthma between 3-5 years of age (HR: 1.19) Pole , 2010[131] 
Maternal bereavement 
N=3.2 million 
1->9 yrs 
 risk of asthma hospitalization Khashan, 2012[259] 
Maternal bereavement 
N = 426.334 
(1-4 yrs) 
N = 493.813 
(7-12 yrs) 
 risk of asthma at 1–4 yrs in boys exposed  
(2nd trimester maternal bereavement ) 
 risk of asthma attack 7–12 yrs in boys 
Fang, 2011[135] 
Prenatal adverse life 
events 
N= 1587 
Until 14 yr 
 asthma and eczema at age 14 yrs 
 asthma in children aged 7 yrs 
Hartwig, 2014[260] 
Maternal bereavement 
N = 750.058 
Until 15 yrs 
 risk of asthma events in children aged 0-3 years 
 asthma in children aged 4-15 years 
Liu, 2015[134] 
Infection 
Antenatal 
Betamethasone 
N=453 
Infants (days 
after birth 
 Early-onset neonatal sepsis (OR 1.25) 
and  death (OR 1.70), if multiple courses 
Vermillion, 2000[124] 
Antenatal steroids 
N=2994 
Infants 48h 
after birth 
 systemic infections (RR 0.56) Roberts, 2000[32] 
Relationship 
dissatisfaction 
Stressful life events 
(30 WOG) 
N= 58530 
Until 1 yr 
 frequency/variety infectious diseases   Henriksen, 2015[245] 
Maternal anxiety (37 
WOG) 
N= 147 
Until 1 yr 
 infant antibiotic use Beijers, 2010[7] 
Antenatal steroids 
N=102 
10-12 yr old 
 hospital admissions because of infectious diseases 
Smolders-de Haas, 
1990[136] 
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Prenatal stress: 
negative life events 
N= 1.7 million 
Until 14 yr 
71% increased risk of severe infectious disease 
hospitalization. 
Nielsen, 2011[137] 
Type I 
diabetes 
Antenatal steroids 
N=505386 
Until 10 yr 
 risk of type 1 (HR: 1.20)  
 risk of type 2 diabetes (HR: 1.51) 
Greene, 2013[139] 
Maternal bereavement 
N = 1.548.746 
2-27 yrs 
 type-1 diabetes, mainly in girls Virk, 2010[138] 
Cancer 
Maternal bereavement 
(spouse or child) 
N=6143772 
Until 14 yr 
 30% risk of any cancer, especially non-Hodgkin 
disease and hepatic cancer 
Li, 2014[142] 
Maternal bereavement 
(parents) 
N= 39002 vs. 
> 11 million 
(database) 
0-43 yr 
 leukemia, Hodgkin’s disease (lymphoma) 
independent bereavement timing  
 testicular cancer,  in 3rd trimester bereavement 
Bermejo, 2007[143] 
OR: odds ratio; RR: relative risk; HR: hazard ratio; RDS Tx: Respiratory Distress Syndrome Treatment; WOG: weeks of gestation;  
Open cells depict prenatal stress exposure and shadowed cells antenatal steroid treatment. Only studies with more than 100 
participants were included 
 
 
23 
 
 BOX 1 Steroid hormones play a fundamental role during 
pregnancy. Endogenous glucocorticoids (CORT: cortisol in 
humans, corticosterone in mouse and rats) rise during the 
second half of pregnancy (top left), and might be further 
increased by maternal stress perception. Additionally, 
exogenous synthetic steroids, such as betamethasone or 
dexamethasone (top right) and prednisolone may be 
administrated during gestation to promote fetal lung 
maturation or to treat autoinflammatory diseases of the 
mother. Endogenous and exogenous glucocorticoids exhibit 
differential binding to plasma globulins: endogenous 
glucocorticoids appear mostly bound to corticosteroid 
binding globulin (CBG) and only in a minor fraction bound to 
albumin (Alb) or free, whereas exogenous glucocorticoids 
appear equitably bound to Alb or free. In contrast to 
dexamethasone and betamethasone, endogenous 
glucocorticoids and prednisolone are good substrates for 
inactivation by placental 11-HSD2 enzyme, which limits 
their transplacental passage. As steroid compounds, 
glucocorticoids readily cross the fetal cell membrane to bind 
the intracellular glucocorticoid receptor (GR, light blue). 
Noteworthy, dexamethasone and betamethasone display a 
higher affinity to GR than the other glucocorticoids. In the 
cytoplasm, inactive GR appear associated to a multiplicity of 
chaperon proteins (green triangles), which are released 
upon glucocorticoid binding. Engagement of the receptor 
elicits rapid non-genomic GR and chaperone protein 
signalling and allows GR translocation to the nucleus. GR can 
modulate gene expression by binding as homodimeric 
transcription factors to the palindromic glucocorticoid 
response elements (GRE) in the DNA. Additionally, GR 
monomers or dimers can interact with other transcription 
factors (pink squares) to activate or repress gene expression. 
Altogether, these regulation of gene expression is called 
(trans)activation or (trans)repression (reviewed in[261-263]). 
Whilst most glucocorticoid induced pathways are mediated 
through binding to the widely expressed GR, glucocorticoids can bind even with higher affinity the mineralocorticoid receptor (MR), 
whose distribution is restricted to fewer fetal cell types than GR. Moreover, the effect of glucocorticoids signalling through MR and 
GR is often dampened by the local co-expression (i.e. in the fetal cells) of the glucocorticoid inactivating enzyme 11β-HSD2.   
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Figure 1 
 
 
Figure 1. Hypothetical scenario depicting mechanisms by which excessive fetal glucocorticoid exposure may affect the fetal immune 
ontogeny resulting in altered postnatal immune responses. Excessive fetal glucocorticoid exposure can result from overwhelming 
maternal glucocorticoid levels, antenatal corticosteroid treatment, or from fetal HPA hyperactivity. Glucocorticoids may favour liver 
(murine E12-E16) or bone marrow (E16.5-birth) erythropoiesis and myeloid hematopoiesis, by promoting (orange arrows) 
haematopoietic stem cell (HSC) differentiation to common myeloid progenitors (CMP) in detriment (blue arrows) of common 
lymphoid progenitors (CLP). Moreover, glucocorticoids may directly affect the bone marrow stromal cells, i.e. osteoblast, which 
through the secretion of soluble factors can modulate HSC migration, proliferation and differentiation activities. Altered 
hematopoiesis might be associated to impaired perinatal neutrophil (Neu) function and humoral (B cell derived) responses. In the 
thymus, where endogenous glucocorticoids are also locally produced towards the end of pregnancy, an excess of glucocorticoids 
results in increased apoptosis of immature doble positive (DP) thymocytes and forces an accelerated maturation of doble negative 
(DN) precursors to fill the vacant niche. By antagonizing TCR signalling or by blunting AIRE-mediated autoantigen transcripts, 
glucocorticoids may affect the process of negative selection, allowing the export of autoreactive CD4 and CD8 single positive (SP) T 
cells. In addition, prenatal glucocorticoids program CD4 T helper (Th) cells towards a Th2 profile. Finally, programming of postnatal 
HPA axis hyperactivity, exhibiting increased levels of corticotropin-releasing hormone (CRH) and arginine-vasopressin (AVP), 
potentiate altered innate and adaptive immune responses, i.e. monocyte (Mo), macrophages or/and dendritic cell (DC) tolerance 
towards pathogens or excessive mast cell degranulation, which would in turn contribute to the prenatal programming of immune 
function to enhance the risk for infection, asthma and other immune diseases. 11-HSD2, 11β-hydroxysteroid dehydrogenase 2; ETP, 
Early Thymocyte Precursors; IgE, Immunoglobulin E; mTEC, medullary Thymic Epithelial Cells; Treg, regulatory T cell. 
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We have addressed the comments of reviewer#1 by adding at different points of the manuscript if the 
comment stated or the work reviewed refers to animal or human research. In addition, we have added a 
comment referring to differences in the timing of development of the immune system in mice and 
human, and the consequences on the windows of susceptibility (highlighted). 
 
As suggested by reviewer#2, we have shortened the manuscript by cutting some less relevant 
paragraphs and sentences, which are highlighted in yellow and crossed in the revised version. Among 
other, we have eliminated the section ‘11beta-HSD1 expression in the uterus’ because, even of 
importance, it is more related to embryo implantation,  and not so much to the development of the fetal 
immune system.  In total, we have now 715 words less in the new version.  
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